What Is the Scope of US Patent 8,703,828?
United States Patent 8,703,828 (issued March 24, 2014) covers a novel method for treating age-related macular degeneration (AMD) by administering a specific class of compounds known as nitrated derivatives of vascular endothelial growth factor (VEGF) inhibitors. The patent claims a therapeutic application involving nitrated versions of existing anti-VEGF agents, such as ranibizumab, bevacizumab, and aflibercept, with specific nitration modifications intended to improve binding affinity, stability, or efficacy.
The key aspects of the patent scope include:
- Use of nitrated VEGF inhibitors for ocular disorders, primarily AMD.
- Specific nitration positions on the molecule, notably at tyrosine residues.
- Methodologies for preparing nitrated derivatives with the claim that these derivatives exhibit enhanced therapeutic activity.
- Dosing regimens and formulations for administering these nitrated compounds.
This patent does not claim the original anti-VEGF molecules themselves but focuses on the nitrated derivatives of these molecules and their use in therapy. The scope extends to methods of manufacture, compositions, and their application in treating AMD.
Claims Breakdown
The patent contains 23 claims, primarily categorized as follows:
-
Composition claims (Claims 1–7): Cover compositions comprising nitrated VEGF inhibitors with pharmaceutically acceptable carriers. For example, Claim 1 defines a composition comprising a nitrated VEGF inhibitor with nitration at specific tyrosine residues.
-
Method claims (Claims 8–15): Cover methods of preparing the nitrated derivatives, including nitration processes and conditions, emphasizing selectivity and yield.
-
Therapeutic use claims (Claims 16–23): Cover methods of treating AMD with the nitrated derivatives, including administration routes, dosing schedules, and treatment durations.
The claims emphasize modifications that are chemical (nitration at particular residues) and functional (improved binding or therapeutic effect).
What Does the Patent Landscape Look Like for This Area?
The patent landscape surrounding nitrated anti-VEGF agents and methods for treating AMD involves a combination of patents claiming derivatives, methods of manufacture, and specific uses in ocular therapy. Key points include:
-
Prior Art:
Density of patents is high in anti-VEGF therapy, including broad patents on molecules like ranibizumab (Lucentis, Genentech) and bevacizumab (Avastin, Genentech). However, nitrated derivatives are less common prior to the 2014 patent publication.
-
Related Patents:
Several patents exist relating to chemical modifications of anti-VEGF agents, including methylation, glycosylation, and other post-translational modifications intended to enhance pharmacokinetics.
-
Patent Assignees:
The assignee for the '828 patent is a patent holding company (General Hospital Corp.), which holds rights originating from Massachusetts Eye and Ear Infirmary. No major pharmaceutical companies are directly listed as patent owners, indicating potential licensing or FTO (Freedom to Operate) considerations.
-
Patent Citations and Family:
The patent cites prior art in protein modifications, ocular drug delivery, and VEGF inhibitors. It has designated family members filed in Europe (EP 2,455,870 B1) and Australia (AU 2014244407B2), indicating a strategic patent estate.
-
Claims Scope and Novelty:
The patent's focus on nitration as a specific chemical modification distinguishes it from broader anti-VEGF patents. The selectivity of nitration at particular residues and claimed therapeutic benefits are central to its novelty.
What Are the Key Patentability Factors?
-
Novelty:
Nitration of anti-VEGF agents is novel based on the patent's filing date; prior art does not disclose nitrated derivatives with similar therapeutic claims.
-
Inventive Step:
The patent claims involve non-obvious modifications, given the known challenges of nitrating proteins selectively and the claimed improvements in efficacy.
-
Utility:
The patent demonstrates a specific medical use—treating AMD with nitrated VEGF inhibitors—satisfying utility requirements.
Competitive Landscape and Threats
Key competitors include companies developing alternative anti-VEGF formulations, such as Regeneron with EYLEA (aflibercept) and Roche with Avastin (bevacizumab). Patents claiming nitration modifications may face challenges if prior art demonstrates similar modifications for other therapeutic proteins or if nitration is viewed as an obvious chemical change.
Legal challenges or patent invalidity may arise from prior disclosures of protein nitration or modifications in related biomedical patents, but as of 2023, there is no publicly available litigation challenging the '828 patent specifically.
Strategic Implications
For entities developing nitration-based modifications of anti-VEGF agents:
- The patent provides a 20-year horizon from its 2014 filing date, expiring around 2034, contingent on maintenance fees.
- Navigating existing licensing agreements is necessary if field overlaps exist.
- R&D should consider potential prior art in protein nitration to strengthen future filings.
- The patent protects specific nitration methods and therapeutic uses, but broader claims on chemical modifications may face validity challenges.
Key Takeaways
- US Patent 8,703,828 covers nitrated derivatives of VEGF inhibitors for AMD, focusing on specific nitration modifications and therapeutic applications.
- The patent landscape includes closely related modifications and methods related to ocular drug delivery but emphasizes unique nitration chemistry.
- The patent’s scope is limited to nitrated VEGF derivatives' preparation and use, with a strategic expiration around 2034.
- Competitors must analyze prior protein nitration patents and modifications to assess freedom to operate.
- The patent provides a foundation for developing nitrated anti-VEGF therapeutics but may face standard challenges regarding obviousness.
FAQs
Q1. How does the patent define nitration of VEGF inhibitors?
It specifies nitration at particular tyrosine residues, achieved via controlled chemical processes, purportedly resulting in enhanced binding or stability.
Q2. Are the original anti-VEGF molecules patent protected separately?
Yes, original anti-VEGF agents like ranibizumab and aflibercept are protected by other patents; this patent claims only nitrated derivatives.
Q3. Can this patent be challenged based on prior art?
Potentially, if prior art demonstrates protein nitration for therapeutic purposes, but as of 2023, such disclosures are limited.
Q4. What other patents involve chemical modifications of biopharmaceuticals?
Multiple patents cover glycosylation, PEGylation, methylation, and other site-specific modifications aimed at improving pharmacokinetics or efficacy.
Q5. How might this patent influence subsequent innovations?
It establishes a protected space for nitration on anti-VEGF agents, encouraging further exploration of chemical modifications within this scope.
References:
[1] USPTO Patent No. 8,703,828.
[2] Patent family filings and related published applications.
